国际医药卫生导报 ›› 2023, Vol. 29 ›› Issue (9): 1201-1204.DOI: 10.3760/cma.j.issn.1007-1245.2023.09.005

• 医学新进展 • 上一篇    下一篇

软骨素聚合因子在乳腺癌中的研究进展

侯长冉  姜京汝  花义同   

  1. 滨州医学院附属医院乳腺外科,滨州 256600

  • 收稿日期:2022-11-10 出版日期:2023-05-01 发布日期:2023-05-21
  • 通讯作者: 姜京汝,Email:jingruyouyou@126.com
  • 基金资助:

    国家自然科学基金(81902702

Progress of chondroitin polymerization factor in breast cancer

Hou Changran, Jiang Jingru, Hua Yitong   

  1. Breast Surgery, Binzhou Medical University Hospital, Binzhou 256600, China

  • Received:2022-11-10 Online:2023-05-01 Published:2023-05-21
  • Contact: Jiang Jingru, Email: jingruyouyou@126.com
  • Supported by:

    National Natural Science Foundation of China (81902702)

摘要:

乳腺癌是全世界女性最常见的癌症,已成为全球性的健康问题。肿瘤学最新领域的研究揭示了软骨素聚合因子(CHPF)在乳腺癌各种生物学行为方面的潜在作用。CHPF是一种型跨膜蛋白,是一种参与硫酸软骨素(chondroitin sulfateCS)延伸的酶,是许多癌症预后不良的新关键分子。目前,CHPF在乳腺癌发生发展中的机制成为研究热点。未来,深入探究CHPF在乳腺癌中的作用及其分子机制,可为乳腺癌的防治及靶向治疗提供新思路。本文将概述CHPF及其在各种恶性肿瘤中的作用,着重介绍CHPF在乳腺癌中的生物功能,有望为抗肿瘤药物研究提供新的治疗靶点,为肿瘤治疗提供新思路。

关键词:

乳腺癌, 软骨素聚合因子, 治疗, 预后, 生物标志物

Abstract:

Breast cancer is the most common cancer in women worldwide and has become a global health problem. Researches in the latest field of oncology have revealed the potential role of chondroitin polymerization factor (CHPF) in the various biological behaviors of breast cancer. CHPF is a type II transmembrane protein, an enzyme involved in the extension of chondroitin sulfate, and a new key molecule with poor prognosis in many cancers. At present, the mechanism of CHPF in genesis and development of breast cancer has become a research hotspot. In the future, deeply exploring the role of CHPF and its molecular mechanism in breast cancer can provide new ideas for the prevention and treatment and targeted treatment of breast cancer. This paper provides an overview of CHPF and its role in various malignancies, focusing on the biological function of CHPF in breast cancer, which is expected to provide new therapeutic targets for anti-tumor drug research and provide new ideas for tumor treatment.

Key words:

Breast cancer, Chondroitin polymerization factor, Treatment, Prognosis, Biomarkers